On the mechanism of action of SJ-172550 in inhibiting the interaction of MDM4 and p53

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Bista, Michal ^a,b   Smithson, David ^c   Pecak, Aleksandra ^b   Salinas, Gabriella ^c   Pustelny, Katarzyna ^b   Min, Jaeki ^c   Pirog, Artur ^b   Finch, Kristin ^c   Zdzalik, Michal ^b   Waddell, Brett ^c   Wladyka, Benedykt ^b   Kedracka Krok, Sylwia ^b   Dyer, Michael A ^c,d,e   Dubin, Grzegorz ^b   Guy, R Kiplin ^c  

^a MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

^b JAGIELLONIAN UNIVERSITY   (Poland)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^d UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^e HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN INHIBITOR; PROTEIN MDMX; PROTEIN P53; SJ 172550; UNCLASSIFIED DRUG; ACETIC ACID DERIVATIVE; BUFFER; MDM4 PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN; PEPTIDE; PYRAZOLE DERIVATIVE;

ALKYLATION; ARTICLE; BINDING COMPETITION; CONTROLLED STUDY; CRYSTALLOGRAPHY; DRUG ACTIVITY; DRUG INHIBITION; DRUG STRUCTURE; HUMAN; HYDROPHOBICITY; MOLECULAR DYNAMICS; PROTEIN AGGREGATION; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN DENATURATION; PROTEIN DOMAIN; PROTEIN STABILITY; STOICHIOMETRY; THERMOSTABILITY; AMINO ACID SEQUENCE; BIOLOGICAL MODEL; CHEMISTRY; DRUG EFFECT; IC 50; METABOLISM; MOLECULAR GENETICS; PLIABILITY; TEMPERATURE;

ACETATES; AMINO ACID SEQUENCE; BUFFERS; HUMANS; INHIBITORY CONCENTRATION 50; MODELS, BIOLOGICAL; MOLECULAR SEQUENCE DATA; NUCLEAR PROTEINS; PEPTIDES; PLIABILITY; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN STABILITY; PROTO-ONCOGENE PROTEINS; PYRAZOLES; TEMPERATURE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84861873122     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0037518     Document Type: Article

References (24)

1. Hanahan D, Weinberg RA, (2011) Hallmarks of cancer: the next generation. Cell 144: 646-674.
2. Vazquez A, Bond EE, Levine AJ, Bond GL, (2008) The genetics of the p53 pathway, apoptosis and cancer therapy. Nat Rev Drug Discov 7: 979-987.
3. Marine JC, Dyer MA, Jochemsen AG, (2007) MDMX: from bench to bedside. J Cell Sci 120: 371-378.
4. Mancini F, Di Conza G, Moretti F, (2009) MDM4 (MDMX) and its Transcript Variants. Curr Genomics 10: 42-50.
5. Wynendaele J, Bohnke A, Leucci E, Nielsen SJ, Lambertz I, et al. (2010) An illegitimate microRNA target site within the 3' UTR of MDM4 affects ovarian cancer progression and chemosensitivity. Cancer Res 70: 9641-9649.
6. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, et al. (2004) In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303: 844-848.
7. Herold JM, Wigle TJ, Norris JL, Lam R, Korboukh VK, et al. (2011) Small-molecule ligands of methyl-lysine binding proteins. Journal of medicinal chemistry 54: 2504-2511.
8. Artz JD, Wernimont AK, Allali-Hassani A, Zhao Y, Amani M, et al. (2011) The Cryptosporidium parvum kinome. BMC genomics 12: 478.
9. Senisterra G, Chau I, Vedadi M, (2011) Thermal Denaturation Assays in Chemical Biology. Assay and drug development technologies.
10. Reed D, Shen Y, Shelat AA, Arnold LA, Ferreira AM, et al. (2010) Identification and characterization of the first small molecule inhibitor of MDMX. J Biol Chem 285: 10786-10796.
11. Popowicz GM, Czarna A, Wolf S, Wang K, Wang W, et al. (2010) Structures of low molecular weight inhibitors bound to MDMX and MDM2 reveal new approaches for p53-MDMX/MDM2 antagonist drug discovery. Cell Cycle 9: 1104-1111.
12. Pazgier M, Liu M, Zou G, Yuan W, Li C, et al. (2009) Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX. Proc Natl Acad Sci U S A 106: 4665-4670.
13. Bernal F, Wade M, Godes M, Davis TN, Whitehead DG, et al. (2010) A stapled p53 helix overcomes HDMX-mediated suppression of p53. Cancer Cell 18: 411-422.
14. Bose P, Ozer H, (2009) Neratinib: an oral, irreversible dual EGFR/HER2 inhibitor for breast and non-small cell lung cancer. Expert Opin Investig Drugs 18: 1735-1751.
15. Kuhn DJ, Orlowski RZ, Bjorklund CC, (2011) Second generation proteasome inhibitors: carfilzomib and immunoproteasome-specific inhibitors (IPSIs). Curr Cancer Drug Targets 11: 285-295.
16. Ocana A, Amir E, (2009) Irreversible pan-ErbB tyrosine kinase inhibitors and breast cancer: current status and future directions. Cancer Treat Rev 35: 685-691.
17. Wallentin L, (2009) P2Y(12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use. Eur Heart J 30: 1964-1977.
18. Feng BY, Shelat A, Doman TN, Guy RK, Shoichet BK, (2005) High-throughput assays for promiscuous inhibitors. Nature chemical biology 1: 146-148.
19. Arnold LA, Estebanez-Perpina E, Togashi M, Jouravel N, Shelat A, et al. (2005) Discovery of small molecule inhibitors of the interaction of the thyroid hormone receptor with transcriptional coregulators. J Biol Chem 280: 43048-43055.
20. Vedadi M, Niesen FH, Allali-Hassani A, Fedorov OY, Finerty PJ Jr, et al. (2006) Chemical screening methods to identify ligands that promote protein stability, protein crystallization, and structure determination. Proc Natl Acad Sci U S A 103: 15835-15840.
21. Hwang JY, Attia RR, Zhu F, Yang L, Lemoff A, et al. (2012) Synthesis and Evaluation of Sulfonylnitrophenylthiazoles (SNPTs) as Thyroid Hormone Receptor-Coactivator Interaction Inhibitors. Journal of medicinal chemistry.
22. Hwang JY, Huang W, Arnold LA, Huang R, Attia RR, et al. (2011) Methylsulfonylnitrobenzoates, a new class of irreversible inhibitors of the interaction of the thyroid hormone receptor and its obligate coactivators that functionally antagonizes thyroid hormone. J Biol Chem 286: 11895-11908.
23. Hwang JY, Arnold LA, Zhu F, Kosinski A, Mangano TJ, et al. (2009) Improvement of pharmacological properties of irreversible thyroid receptor coactivator binding inhibitors. Journal of medicinal chemistry 52: 3892-3901.
24. Lavinder JJ, Hari SB, Sullivan BJ, Magliery TJ, (2009) High-throughput thermal scanning: a general, rapid dye-binding thermal shift screen for protein engineering. Journal of the American Chemical Society 131: 3794-3795.